Podcasts about Saag

In episode 50 of Going anti-Viral, Dr Yvonne Maldonado joins host Dr Michael Saag to discuss the respiratory syncytial virus (RSV) vaccine and the vaccine approval process in the United States. Dr Maldonado is a Professor in the Stanford University School of Medicine where she has achieved national and international recognition for her scholarship in the epidemiology and control of infectious diseases. She has served on several national and international committees including, until recently, the CDC Advisory Committee on Immunization Practices (ACIP). Dr Maldonado and Dr Saag provide an overview of RSV including the history of RSV vaccine research and development and provide an update on the availability of RSV vaccine in adults but not in children. They also discuss the risk of severe disease in children and the limited treatments available. Dr Maldonado and Dr Saag also discuss the process for vaccine approvals in the United States. Specifically, they review the role of the ACIP committee in vaccine approvals and provide an update on the recent dismissal of all of the prior members of the committee, which included Dr Maldonado. They discuss the potential impact that this will have on the review of all vaccines and the overall impact on public health. 0:00 – Introduction 1:30 – Overview of RSV including the history of RSV vaccine research and development 5:08 – Status of RSV vaccine availability in adults and children  8:15 – Discussion of the length of RSV vaccine protection and the differences in RSV respiratory disease between children and adults 10:17 – Risk of severe disease from RSV in children 12:22 – Overview of the vaccine approval process in the United States and how the CDC ACIP committee operates 19:27 – Discussion of the recent dismissal of all members of the ACIP including Dr Maldonado and her concern for the process of vaccine approval moving forward 23:54 – The vetting process for new members of the ACIP and assessment of newly appointed members 27:20 – How the recent personnel changes at the ACIP and other federal agencies impact public health 32:08 – Discussion of the public commitment and support for vaccination moving forward__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In episode 49 of Going anti-Viral, Dr Judith Currier joins host Dr Michael Saag to discuss Next-Gen HIV Prevention and Treatment. Dr Currier is a Professor of Medicine at UCLA and has more than 25 years of experience in the design, implementation, conduct, and analysis of clinical trials to optimize antiretroviral management of HIV and related complications. Dr Currier and Dr Saag provide an overview of why new antiretroviral drugs are needed and discuss the successful return on investment in biomedical research. They also provide a detailed review of long-acting antiretroviral drugs and discuss the state of current research for new options, including a discussion of lenacapavir. Finally, they share their concerns for what is at stake if attempts to cut the federal research budget are successful and the disruption it will bring to the progress that has been made in HIV care and other viral diseases.  0:00 – Introduction1:20 – Overview of why new antiretroviral drugs are needed2:57 – The return on investment in biomedical research3:52 – Overview of the need for long-acting antiretroviral drugs and options available 8:23 – Review of the current research and prospects for new long-acting therapies 12:59– Discussion of lenacapavir and the potential benefits for prevention and treatment 14:21 – Summary of other drugs on the horizon that may be potential treatments18:39 – Overview of the different methods for delivery of drugs21:11 – Impact of potential budget cuts on HIV research, on people with HIV, and on other viral diseases __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Mary Fisher joins host Dr Michael Saag to discuss Communicating the Importance of Science and Research to the Public. Ms Fisher is an artist, author, and activist, who has spent a lifetime giving voice to the voiceless. Her historic speech at the 1992 Republican Convention, A Whisper of AIDS, has been named one of “forty famous speeches that have had long-term effect on society.” In this episode, Ms Fisher discusses her history of activism including her work in Africa before and after the arrival of PEPFAR and the concern for the many communities she worked with given the termination of USAID. Ms Fisher also discusses her new book Uneasy Silence: An activist seeks justice and courage over a lifetime of change where she and Dr Saag stress the importance of speaking out for scientific research given the impact it has on patient care and saving lives. 0:00 – Introduction1:17 – History of Ms Fisher's activism 4:11 – Impact of Ms Fisher's work in Africa and discussion of the quality of life before and after PEPFAR 10:05 – The impact of the elimination of USAID on people with HIV, nutrition, and other diseases 14:36 – Discussion of Ms Fisher's book Uneasy Silence: An activist seeks justice and courage over a lifetime of change20:12 – Why scientific research is important and the impact of cuts to the research budget at NIAID28:55 – The need to speak out for science, the practice of medicine, and care for those in need of careRelated Resources:Uneasy Silence: An activist seeks justice and courage over a lifetime of change Amazon  A Whisper of AIDS YouTube Project Angel FoodEpisode 43 YouTube | Apple Podcasts with Dr Izukanji SikazweVoices in HIV Research and Global Health, from the Scientists, the Labs, and the Community YouTube __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going Anti-Viral, Rebecca Denison joins host Dr Michael Saag as a follow-up discussion to her Martin Delaney presentation at CROI 2025: 40+ Years of HIV: What's Changed, What Hasn't, What Shouldn't, What Must. Ms Denison is an HIV-positive writer, educator, mother, and founder of WORLD, Women Organized to Respond to Life-threatening Diseases. Dr Saag and Ms Denison reflect on her history of living with HIV and her 40 + years as an HIV activist. They discuss the impact that recent cuts at USAID and PEPFAR are having international efforts to reduce HIV transmission and the loss in trust in healthcare practitioners since programs have been terminated. They also discuss concerns about cuts to federal funding for HIV care programs in the US and the impact of recent loss of staff expertise at federal agencies. Finally, Dr Saag and Ms Denison ask all care clinicians to share their stories to their communities as a way of becoming advocates for the importance of HIV care.0:00 – Introduction2:41 – History of Ms Denison's activism in HIV and AIDS 4:58 – Discussion of the gap in HIV care since the termination of USAID and PEPFAR contracts8:29 – The loss of trust in global HIV health care practitioners and stories of growing HIV transmission since funding for care has been terminated14:24 – Risks of funding cuts to domestic HIV care programs and Medicaid18:02 – How a younger generation of advocates can learn from the history of HIV activism19:51 – The message sent by the reorganization of HHS and the dismissal of leading HIV experts22:06 – How clinicians can be an advocates for HIV care Watch/Listen to related episodes:Special Episode YouTube | Apple Podcasts 40+ Years of HIV: What's Changed, What Hasn't, What Shouldn't, What Must. The Martin Delaney presentation at CROI by Rebecca DenisonEpisode 43 YouTube | Apple Podcasts Innovations in HIV Service Delivery with Dr Izukanji Sikazwe__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going Anti-Viral, Dr Raymond Schinazi joins host Dr Michael Saag for an in-depth conversation about the development of a cure for hepatitis C. Dr Schinazi, the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University, shares insights from his distinguished career in antiviral research and development. He begins by outlining his background and long-standing interest in antiviral therapies, including groundbreaking work in HIV treatment. The conversation then shifts to his pivotal role in the development of sofosbuvir, a breakthrough direct-acting antiviral drug in the cure for hepatitis C, and the importance of NS5A inhibitors in antiviral drug regimens. Dr Schinazi also offers a rare behind-the-scenes look at the business and regulatory journey of bringing a transformative therapy to market, reflecting on the personal impact of this milestone. The episode concludes with a discussion of his current research into potential treatments for hepatitis B. 0:00 – Introduction1:24 – Overview of Dr Schinazi's background and his interest in antiviral therapy2:56 – Discussion of Dr Schinazi's work in the development of antiviral agents for HIV4:45 – Background on the development of sofosbuvir for the cure of hepatitis C10:01 – The role of NS5A inhibitors in treatment12:42 – History of bringing hepatitis C treatment to market14:25 – Discussion of the effectiveness of NS5A inhibitors 16:49 – The risk of reinfection and review of the basic science behind pharmaceuticals for hepatitis C18:22 – How the discovery of a hepatitis C cure impacted Dr Schinazi personally25:16 – Overview of Dr Schinazi's current research in Hepatitis B__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Graham Hatfull, a Professor of Biological Sciences at the University of Pittsburgh. Dr Hatfull joins Dr Saag to discuss Bacteriophages for the treatment of antimicrobial-resistant (AMR) bacterial infections. Dr Hatfull provides an overview of the types of bacteriophages and how they can be used to treat antimicrobial-resistant bacteria. Dr Hatfull and Dr Saag discuss the challenges of treating bacterial infections with phages given the diversity and complexity of the different types of bacteria and bringing phage treatments to scale. Finally, they discuss what research is needed to overcome the challenges of phage treatment and look to the future where technology enables synthetically produced phages to provide targeted therapy to antimicrobial resistant bacteria.0:00 – Introduction1:05 – Overview of bacteriophages and Dr Hatfull's interest in phage research2:46 – How phages can be used clinically for antimicrobial-resistant bacteria4:34 – Differences between the 2 types of phages: lytic phages and temperate phages6:01 – How phages are used to target specific types of bacteria9:37 – The challenge of phage treatment matching and natural CRISPR processes within bacteria15:16 – Understanding the phage genome diversity 18:59 – Discussion of therapeutic uses of phages28:32 – Prospect of phages for future treatments including synthetic phagesResources: Harnessing the Power of Bacteriophages with Dr Robert Schooley:YouTube: https://youtu.be/_BUpDRNhMsQApple Podcasts: https://podcasts.apple.com/us/podcast/episode-10-harnessing-the-power-of-bacteriophages/id1713226144?i=1000647215580 Exploring Bacteriophage Therapy for Drug-Resistant Bacterial Infections Robert T. Schooley, MD: https://www.iasusa.org/wp-content/uploads/2023/03/31-1-23.pdf  The inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics: https://www.iasusa.org/bacteriophage-conference/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Annemarie M. Wensing, a Clinical Virologist at the University Medical Center Utrecht and an Honorary Professor at the University of the Witwatersrand in Johannesburg. Dr Wensing joins Dr Saag to discuss the recently released IAS–USA 2025 Update of the Drug Resistance Mutations in HIV-1. Dr Wensing discusses the influence of Dr Charles Boucher in developing her interest in the topic of HIV drug resistance and Dr Wensing and Dr Saag provide an overview of HIV drug resistance and testing. Dr Wensing also provides advice to clinicians on how to manage patients who experience drug resistance. Dr Wensing and Dr Saag then discuss an upcoming report soon to be published that addresses the potential role and the important limitations of HIV DNA resistance testing. Finally, they address the topic of drug resistance in the absence of resistance mutations and look ahead to what the future holds for the field of HIV resistance. 0:00 – Introduction 1:30 – Dr Wensing reviews the influence that Dr Charles Boucher played in her development as an investigator and her interest in HIV resistance 2:46 – Discussion of why there is HIV drug resistance 4:48 – Overview of drug resistance testing, genotypes and phenotypes 7:25 – New recommendations from the IAS-USA resistance mutation panel 9:50 – Advice to clinicians on managing drug resistance 16:16 – Discussion of HIV DNA resistance testing 21:26 – Understanding drug failure in the absence of resistance mutations  24:49 – Predictions about the future Resources:  IAS–USA Drug Resistance Mutations Chart: https://www.iasusa.org/hiv-drug-resistance/hiv-drug-resistance-mutations/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Izukanji Sikazwe, the Chief Executive Officer for the Centre for Infectious Disease Research in Zambia (CIDRZ). Dr Sikazwe joins Dr Saag to provide an overview of her symposium presentation at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) entitled Innovations in HIV Service Delivery: Building a Path Forward with Those Left Behind. Dr Sikazwe discusses her career journey in treatment of HIV in Zambia and her path to CIDRZ. Dr Sikazwe and Dr Saag discuss the history of HIV and AIDS in Zambia and address the impact that PEPFAR had on the disease when it arrived in the country in 2004. They discuss how PEPFAR has operated in Zambia and provide a current overview of the sudden cancellation of USAID contracts on those receiving HIV care and treatment and other health services. Finally, they look ahead given the current disruptions on how Zambia and other countries can move forward to meet the needs of those in need of care.0:00 – Introduction1:41 – Dr Sikazwe reviews her path to CIDRZ5:21 – History of HIV and AIDS in Zambia and discussion of stigma7:53 – The impact of PEPFAR's arrival in Zambia and Dr Sikazwe's personal history with treatment during that time13:37 – How PEPFAR works in Zambia16:56 – Impact of recent decision by the US government to cancel USAID contracts22:31 – Disruption to other health services that USAID has supported in Zambia23:50 – Response from the government in Zambia24:46 – Status of HIV in Zambia prior to cancellation of USAID contracts25:50 – The best-case scenario for people living with HIV globally and closing remarksResources: CROI 2025: https://www.croiconference.org/Centre for Infectious Disease Research in Zambia (CIDRZ): https://www.cidrz.org/   PEPFAR: https://www.state.gov/pepfar/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

This episode of Going anti-Viral, features Rebecca Denison, who gave the Martin Delaney Presentation, entitled 40+ Years of HIV: What's Changed, What Hasn't, What Shouldn't, What Must, at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI). Ms. Denison is the founder of Woman Organized to Respond to Life-threatening Diseases or (WORLD).  Resources: CROI 2025: https://www.croiconference.org/Woman Organized to Respond to Life-threatening Diseases or (WORLD): https://womenhiv.org/Link to video of presentation: https://youtu.be/CutIwfkv8oUMore on the Martin Delaney Presentation: https://www.croiconference.org/presenters/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Tonia Poteat, a professor in the Duke University School of Nursing and co-director of the Duke SGM Wellness Program. Dr Poteat joins Dr Saag to provide an overview of a Themed Discussion session that she is leading at CROI 2025 entitled Meeting the Treatment and Prevention Needs of Transgender Women. Dr Poteat and Dr Saag address the 3 most common challenges faced in the care of transgender persons: uninformed clinicians, societal discrimination, and efforts by governments to limit the rights of transgender persons. They discuss efforts to educate clinicians and summarize the resources that are available to provide care to transgender persons facing stigma and discrimination. They also discuss efforts to take legal action against discriminatory policies. Finally, Dr Poteat and Dr Saag look ahead to the next five years of transgender care and provide advice to all involved in the care of transgender persons during a challenging time. 0:00 – Introduction1:26 – Overview of Dr Poteat's background and research interests3:42 – Most common challenges encountered by transgender women4:59 – Educating clinicians about care for transgender women9:46 – Resources for clinicians to learn about managing stigma and discrimination11:24 – Efforts by governments to limit transgender care16:14 – Overview of the Themed Discussion session at CROI 202519:07 – Looking ahead to the next five years in transgender careResources: CROI 2025: https://www.croiconference.org/IAS-USA webinar: Gender-Affirming Hormone Care for People With HIV: https://www.iasusa.org/events/webinar-2024-poteat/AIDS Education and Training Center: https://aidsetc.org/  World Professional Association for Transgender Health: https://wpath.org/  Trans Lifeline: https://translifeline.org/ Trevor Project: https://www.thetrevorproject.org/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Joseph Eron, Professor of Medicine at University of North Carolina (UNC) about the topic of his upcoming presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025: HIV Cure Research: State of the Art and Navigating Presentations at CROI 2025. Dr Eron discusses the state of HIV cure research including a detailed discussion of why it has been so difficult to develop a cure for HIV. Dr Saag and Dr Eron discuss the difference between HIV cure and functional cure and provide a detailed overview of cure research efforts looking at blocking and locking HIV in human DNA. Dr Saag and Dr Eron also discuss the potential for “molecular scissors” (CRISPR-Cas9) to cure HIV. Finally, they provide an overview of cure research that will be presented at CROI, highlighting the plenary presentation by Dr Ole Søgaard at CROI on Monday March 10 entitled HIV Cure: A Translational Research Perspective. For more information about the topic of this episode, listen to an earlier episode of Going anti-Viral where Dr Saag discusses Vaccine Development with Dr Richard Koup, see links in the resources below. 0:00 – Introduction1:31 – Defining cure in the context of HIV4:56  – Why is it so hard to cure HIV7:56 – What is functional cure11:47 – Description of the concept of “block and lock” in human DNA14:33 – Discussion of tat inhibitors – blocking of HIV regulatory genes18:02 – Prospect of using “molecular scissors” (CRISPR-Cas9) as a cure23:13 – Highlights in HIV cure research at CROI and closing remarksResources: CROI 2025: https://www.croiconference.org/Going anti-Viral Episode 4 – A Deep Dive into Vaccine Development with Dr Richard Koup: Apple Podcasts: https://podcasts.apple.com/us/podcast/episode-4-a-deep-dive-into-vaccine-development-with/id1713226144?i=1000637677124 YouTube: https://youtu.be/nXeMt3GMj4Q __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Diane Havlir, Professor of Medicine at the University of California San Francisco. Dr Havlir currently serves as Chair of the Scientific Program Committee for the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) and joins Dr Saag to provide a preview of CROI 2025. Dr Havlir provides an overview and history of CROI along with a summary of how the program is developed. Dr Saag and Dr Havlir review why CROI is unique among scientific meetings: leading scientific advances, poster sessions, and the focus on supporting new investigators. They also discuss expected hot topics from CROI such as: HIV treatment and cure, STI prevention, weight management, aging and HIV, as well as pediatric and adolescent care. Dr Saag and Dr Havlir provide an overview of resources that will be available to those who will not attend CROI in person. Finally, they discuss the value of CROI during a challenging time for all involved in the field of HIV research, care, and treatment.0:00 – Introduction1:36 – Overview and history of CROI4:12 – What makes CROI unique6:21 – Discussion of how the CROI program is developed both abstract and invited presentations11:04 – How attendees can interact at CROI12:06 – Features of poster abstract sessions and poster hall13:42 – CROI focus on new investigators17:55 – Hot topics at CROI 202520:45 – Resources for people not attending CROI22:26 – Value of CROI during a challenging time and closing remarksCROI Resources: https://www.croiconference.org/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Andy Pavia of the University of Utah for an update on COVID-19. Dr Pavia and Dr Saag review COVID-19 cases and deaths in 2024 including a discussion about the reasons why deaths have declined compared with earlier years in the pandemic. They also review Long COVID and challenges clinicians face with treatment. Dr Pavia provides a detailed review of COVID-19 vaccines and effectiveness including recommendations on who should be vaccinated. Dr Saag and Dr Pavia review COVID-19 testing, including home testing and antiviral (including monoclonal antibody) treatments. They also discuss how best to provide early treatment to persons at high risk of developing severe disease. Finally, they provide predictions for the future including possible improvements in next generation of COVID-19 vaccines.0:00 – Introduction1:21 – COVID-19 cases and deaths in 20243:21 – Discussion of reduction in deaths 5:11 – Evolution of COVID-19 immunity and discussion of Long COVID12:37 – Challenges in treating Long COVID16:20 – Review of data on effectiveness of COVID-19 vaccines and current recommendations on who should receive a vaccine19:10 – Recommendations on use of antiviral treatments and testing – including recommendations for persons at high risk for developing severe disease23:16 – Discussion of use of remdesivir24:44 – Recommendations for use of pemivibart in persons who are immune compromised 26:30 – Predictions for future therapies and vaccines 28:11 – Summary and closing remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Melanie Thompson who is a clinical researcher and provider of HIV clinical care in Atlanta, Georgia. As Principal Investigator and Executive Director of the AIDS Research Consortium of Atlanta (ARCA), she has led over 400 studies of HIV treatment and prevention and is recognized as an expert in the treatment of patients with HIV. In the episode, Dr Thompson and Dr Saag discuss the recently released 2024 update of primary care guidance for providers who care for persons with HIV by the HIV Medicine Association of the Infectious Diseases Society of America (see links in resources below). They address topics such as telemedicine, outreach to underserved populations, and how to create a welcoming clinic to improve retention in care. They discuss how HIV providers have been leaders in primary care in areas like hepatitis and address how to bring future generations of providers into HIV medicine. Finally, they address the importance of providers being advocates to their elected representatives about HIV medicine and that providing care to individuals, no matter who they are and where they come from, improves overall public health.0:00 – Introduction1:30 – A discussion of Dr Thompson's background in HIV medicine and transition from primary care to focus on HIV4:54 – What's new in the recently released primary care guidelines for persons with HIV 8:40 – Discussion of new recommendations in how providers can manage outreach, including providing mobile care to individuals with substance use disorder and unstable housing15:15 – Treatment of hepatitis as an example of how HIV medicine has led the way in providing primary care 17:04 – Review of guidance on substance use disorder including the use of Narcan and Buprenorphine19:14 – Reflections on the importance of providers being advocates to their elected representatives  24:10 – A discussion of how to create a future generation of HIV providers whether from internal medicine or infectious diseases, or both28:05 – Closing remarks  ResourcesHIV Medicine Association - https://www.hivma.org/HIVMA/IDSA HIV Primary Care Guidance - https://academic.oup.com/cid/advance-arti__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

This episode of Going anti-Viral features an IAS–USA Dialogue titled "Latest Update on Urgent Viral Outbreaks," a panel discussion held on January 15, 2025. This IAS-USA Dialogue is a must listen as our distinguished panel of infectious diseases experts dives deep into some of the most pressing public health challenges facing the world today. Moderated by Carlos del Rio, MD, a Distinguished Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine, this Dialogue brings together world-class experts Yvonne Maldonado, MD, Peter Chin-Hong, MD, and Jason Zucker, MD, to discuss the latest news on urgent and emerging viral outbreaks, including mpox, avian flu (H5N1), respiratory syncytial virus (RSV), measles, human metapneumovirus, and COVID-19/long COVID.The panel also reflects on the alarming erosion of public trust in public health experts, which has been compounded by misinformation and the long-term effects of the COVID-19 pandemic. 0:00 – Introduction 2:27 – Update on mpox including treatment options11:09 – Discussion of avian flu (H5N1), influenza, and vaccination in human and animals27:36 – Impact of avian flu (H5N1) on dairy and other agriculture industries and the role of public health in supporting the economy32:47 – Impact of recent study on Tamiflu in treatment recommendations and discussion of Biloxivir37:37 – Update on COVID-19 – vaccination, treatment with Paxlovid, other treatment options, and long COVID48:27 – Recent updates on respiratory syncytial virus (RSV) and vaccination 52:03 – Discussion of human metapneumovirus54:25 –Impact of misinformation on the reduction in measles vaccinations and the health risks of measles to the population at large 59:54 – Concluding remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Laura Cheever who was, until recently, the Associate Administrator of the HIV/AIDS Bureau at the Health Resources and Services Administration (HRSA). She joined HRSA in 1999 when she served as the national director of the Ryan White AIDS Education and Training Center program. Dr Cheever is Board Certified in Infectious Diseases and continues to provide clinical care for patients with HIV. Dr Cheever describes her early work at HRSA and the Ryan White HIV/AIDS Program. Dr Cheever and Dr Saag then discuss quality measures adopted to demonstrate program effectiveness and the impact these efforts had on funding. They also discuss the staff in the program and their role in working with local providers. They address the role that private insurance, the Affordable Care Act, and different presidential administrations play in the services of the program as well as work left to be done and look ahead to the next ten years of HIV care.0:00 – Introduction1:40 – A discussion of Dr Cheever's early years at the Health Resources and Services Administration (HRSA)7:51 – Implementation of national quality measures for HIV care using data collection through CAREWare11:41 – How did new information impact decision making regarding Ryan White funding decisions15:04 – Impact of changing guidelines on direction given to the Ryan White clinics19:26 – The staff at HRSA and the impact of potential budget cuts on the program24:05 – The role private insurance and the Affordable Care Act had in providing treatment through the Ryan White program 25:10 – Do different presidential administrations influence the services of the Ryan White program27:34 – Discussion of the work left to be done 29:29 – Predictions for the next ten years of HIV care and closing remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Kevin Carmichael of the Arizona Department of Health Services about the unique challenges caregivers faced in addressing the HIV/AIDS pandemic. Dr Carmichael is a family physician who began work in HIV in 1983 while in medical school in Miami, Florida. During his residency at the University of Miami, Dr Carmichael co-authored one of the first written guidance for clinical HIV care “HIV/AIDS: A Primary Care Handbook.” Dr Saag and Dr Carmichael discuss their shared history in caring for people during the early years of HIV and AIDS in the 1980s and 1990s. They also discuss the challenges in managing families of people with AIDS. Dr Carmichael then reflects upon the transition in the care of HIV in 1995 when protease inhibitors became available, effectively the start of turning HIV into a manageable chronic disease. Finally, Dr Saag and Dr Carmichael provide thoughts for younger practitioners currently involved in HIV management.0:00 – Introduction1:22 – A discussion of the early years of HIV and AIDS care in the 1980s7:43 – How Dr Carmichael came to focus on HIV and AIDS care12:36 – Dr Carmichael's transition to care in Arizona and differences from his time in Miami16:08 –Discussion of advanced AIDS and working with families of people with HIV at the time23:12 – The arrival of protease inhibitors in 1995 and the transition to management of a chronic disease31:00 – Closing remarks and reflections for younger practitioners involved in HIV care __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Episode 33 - Overview of Travel Medicine: Vaccines, Outbreaks, and More - Dr David Freedman In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr David Freedman of the University of Alabama at Birmingham to provide an overview of travel medicine: vaccines, outbreaks, and more. Dr Freedman is a professor of infectious diseases and his research is focused on clinical tropical medicine, including the development of surveillance networks to characterize infectious disease morbidity in travelers and migrants. Dr Saag and Dr Freedman provide an overview of worldwide outbreaks such as: mpox, H5N1, Marburg virus, Ebola, dengue fever, chikungunya, and Zika virus. Dr Freedman discusses the treatments and vaccines available for each of these outbreaks. They also address the clinical challenges of treating individuals with emerging infections of unknown origin. Finally, Dr Saag and Dr Freedman address the acute setting of treating rabies exposures from bats and other wild animals.0:00 – Introduction1:11 – Overview of surveillance networks and current areas of concern4:01– Discussion of mpox outbreaks including a new clade in the Democratic Republic of the Congo7:10 – Risk of H5N1 human transmission 10:07 – Update on Marburg virus disease 12:22 – Current status of Ebola disease and availability of monoclonal antibodies for treatment15:53 – Overview of outbreaks in the Caribbean: dengue fever and chikungunya 25:08 – Update on Zika virus26:36 – Discussion of how to clinically address cases of emerging viruses like Oropouche virus29:50 – How to prevent and treat rabies exposures from bats and other animals__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Rajesh Gandhi of Harvard Medical School and Massachusetts General Hospital about the new IAS-USA recommendations for HIV treatment and prevention. Dr Gandhi is the Chair of the guidelines panel, which published its recommendations in the Journal of the American Medical Association on December 1, 2024. Dr Gandhi and Dr Saag discuss the process by which the updated guidelines were created and provide an update on what's new in the current edition. They address other important topics like how to treat patients with opportunistic infections, guidance on when to change therapy, and strategies for preventing HIV acquisition. Finally, Dr Gandhi makes recommendations for those using the guidelines, especially those using them for the first time.0:00 – Introduction1:19 – Overview of the guidelines' creation process3:52– New recommendations on when to start antiretroviral therapy6:37 – New guidance on what regimens to start9:34 – Discussion of other agents like bictegravir and dolutegravir in pregnancy10:45 – How to treat patients with an opportunistic infection 14:09 – Concern about immune reconstitution inflammatory syndrome (IRIS)16:33 – Guidance on when to change therapy and providing support21:18 – How do the guidelines help people stay healthy – management of cancer, cardiovascular risk, and weight gain24:41 – Discussion on prevention of HIV and sexually transmitted diseases30:19 – What could not be addressed in the guidelines33:17 – Final comments and how to use the guidelinesResources: https://jamanetwork.com/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Support the D.A.W.G.Z. @ patreon.com/MSsecretpod Watch 'Breaking Points' w/ Saagar & Krystal  Go See Matt Live in Irvine CA Next Wknd @ mattmccusker.com/dates Go See Shane Live @ shanemgillis.com Yo0o0o0o0o0. Hope you're all having a good week. Here's the public unveiling of the new set up (previously seen on the patreon). Cusk is blessed by Saag this week and the two chop it up for like 2 hrs. Hot mf cast. Check out Breaking Points. Please enjoy. God Bless.  Download the PrizePicks app or visit https://prizepicks.onelink.me/LME0/DRENCHED today and use code Drenched to get $50 instantly after you play your first $5 lineup This episode is brought to you by BetterHelp. Give online therapy a try at betterhelp.com/MSSP and get on your way to being your best self. The Mountain is calling, you should answer #DoTheDew #MTNDEW Shop now @ https://lets.shop/2141/dothedew Support the show & get Lucy Breakers for 20% off & free shipping at https://www.lucy.co promo code DRENCHED

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Kenneth Sherman of Massachusetts General Hospital and Harvard Medical School about the possibility of a cure for hepatitis B. The World Health Organization estimates that 254 million people were living with chronic hepatitis B globally in 2022. Dr Saag and Dr Sherman discuss the lifecycle of hepatitis B including the role that covalently closed circular DNA (cccDNA) plays in the hepatitis B virus (HBV) replication cycle. Dr Sherman defines functional cure and provides an overview of the most promising cure strategies. They also discuss whether antiretroviral drugs like tenofovir, used in the treatment of HIV, can contribute toward a functional cure of hepatitis B. Dr Sherman discusses other strategies like capsid assembly modulators (CAMs), monoclonal antibodies, and toll-like receptor (TLR) agonists. Finally, they discuss the effectiveness of the hepatitis B vaccine in prevention and look forward to the future by considering a timeline for a cure based on the status of ongoing clinical trials. 0:00 – Introduction1:23 – Overview of the lifecycle of hepatitis B 5:29 – Discussion of the most promising cure strategies7:11 – Defining functional cure10:56 – The role of drugs like tenofovir in a functional cure 13:39 – Targets that can affect viral production 16:04 – Potential of capsid assembly modulators (CAMs)18:03 – Other strategies like immune modulators and monoclonal antibodies22:29 – Interest in toll-like receptor (TLR) agonists and therapeutic vaccines24:32 – Outlook for the future and the effectiveness of a hepatitis B vaccine in prevention __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Jason Zucker of Columbia University and the New York City STD Prevention Training Center about mpox and the mpox outbreak. Dr Saag and Dr Zucker discuss the 2 clades of mpox, how it is transmitted, and which clade is associated with the most recent mpox outbreak. They also discuss how to test for mpox and how people with HIV present with mpox based on their HIV viral load. Dr Zucker gives a detailed update on the STOMP (Study of Tecovirimat for Human Mpox Virus) trial that evaluates the efficacy of the antiviral tecovirimat, also known as TPOXX, for the treatment of mpox. They also address the role of vaccination in mpox, its uptake and efficacy. Finally, Dr Zucker offers his perspective on how practitioners and public health officials can address ongoing mpox outbreaks in the US and globally, including a second public health emergency of international concern that was declared in the Democratic Republic of the Congo and surrounding countries in August by the World Health Organization (WHO).0:00 – Introduction1:25 – Description of mpox and its 2 clades2:07 – Overview of the current mpox outbreak3:11 – Mpox transmission4:29 – Mpox in people with HIV6:35 – Testing for mpox9:05 – The STOMP study, enrollment, and effectiveness of tecovirimat15:58 – The role for vaccination for mpox and who should receive it20:38 – Outlook for the future__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Jennifer Kates of KFF to compare and contrast health care policies from different sides of the aisle. Dr Kates provides an update on the Patient Protection and Affordable Care Act (ACA) and efforts to repeal the healthcare program in the United States. Dr Saag and Dr Kates also discuss the status of Medicaid expansion in the US and the impact of access to care in states where Medicaid has been expanded. They also discuss the impact of the Ryan White HIV/AIDS Program on healthcare for people with HIV and the long-term outlook for funding for the program. In addition, there is a detailed overview and outlook of funding for the 340B Drug Pricing Program that allows eligible hospitals and other healthcare organizations to purchase outpatient drugs at a discount from pharmaceutical manufacturers. Finally, Dr Saag and Dr Kates discuss the erosion of trust in science and public health officials in the US and reasons to be optimistic for the future.0:00 – Introduction1:15 – Update on the ACA3:19 – Discussion of efforts to repeal the ACA5:32 – Status of Medicaid expansion in the US8:56 – Overview of access to HIV care through Ryan White 10:37 – Access to health insurance coverage through Ryan White 12:31 – What is 340B funding?15:45 – Possible pressures on 340B funding 17:45 – Outlook for Ryan White funding and availability of PrEP in the program21:34 – Discussion of the erosion of trust in science and public health 26:42 – Outlook for the future__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

This episode of Going anti-Viral features an IAS–USA Dialogue titled "Latest Update on Urgent Viral Outbreaks," a panel discussion held on October 4, 2024. Dr Carlos del Rio from Emory University serves as moderator and welcomes 3 distinguished panelists: Dr Yvonne Maldonado from Stanford University, Dr Peter Chin-Hong from the University of California San Francisco, and Dr Paul Sax from Brigham and Women's Hospital. The episode covers various pressing topics, including updates on COVID-19, avian flu, mpox, and other viral diseases. Discussions touch on vaccines, their effectiveness, public health approaches, and current research.0:00 – Introduction and overview of ongoing viral outbreaks3:59 – Update on respiratory viruses and vaccination – seasonal flu, RSV, and COVID-1912:17 – Discussion of monoclonal antibody treatment for COVID-1914:15 – Update on the use of Paxlovid for COVID-1918:48 – COVID-19 vaccination – protein vaccines vs. mRNA vaccines22:48 – Update on pertussis28:54 – Discussion of seasonal influenza and vaccination32:55 – Effectiveness of shingles and RSV vaccines 35:57 – Discussion of vaccination during pregnancy40:02 – Audience questions43:04 – Update on H5N1 (avian flu) outbreak52:00 – Update on Marburg virus outbreak in Rwanda55:43 – Discussion of mpox outbreak in central Africa59:29 – Concluding remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Carolyn Chu and Dr Lealah Pollock from the University of California San Francisco about the National Clinician Consultation Center (NCCC). The NCCC offers guidance to health care practitioners on HIV, hepatitis, and substance use. Dr Chu and Dr Pollock discuss the most common questions asked by clinicians to the NCCC warm line such as: infant feeding by people with HIV, antiretroviral treatment (ART) for pregnant people with HIV, and the use of long-acting antiretroviral drugs. They also discuss how they respond to questions about the latest developments in preexposure prophylaxis (PrEP) care, care for people with sexually transmitted infections (STIs), and health care practitioner exposures. Finally, they share their thoughts about working for the NCCC and the service they offer to US-based clinicians. 0:00 – Introduction1:31 – History and overview of the services provided by the NCCC 4:31 – A common question – infant feeding in people with HIV10:03 – ART for pregnant people with HIV13:53 – Questions about long-acting antiretroviral drugs16:55 – Interpretation of resistance-associated mutations18:30 – The NCCC warm line service model20:34 – Questions about administering PrEP and impact of recent developments in PrEP research26:08 – Questions about postexposure prophylaxis (PEP) for STIs27:25 – Recommendations for health care practitioner exposures29:17 – Final thoughts and closing remarks Resources:Contact the National Clinician Consultation Center (NCCC):https://nccc.ucsf.edu/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Sandra Springer from the Yale School of Medicine about the substance use disorder epidemic. Dr Springer describes the history of the epidemic and the recent crisis of overdose deaths in the United States. She talks about the increase in overdose deaths since 1999 due to prescription opioids. Dr Saag and Dr Springer review how HIV practitioners can manage patients with substance abuse disorder, including a discussion of how to manage patients undergoing withdrawal. Finally, they address harm reduction strategies available to practitioners and new data showing a reduction in overdose deaths, providing long-term hope for the effectiveness of these strategies. But they note that more research, funding, and outreach is needed to meet the risks that opioid and non-opioid substances pose in the future.0:00 – Introduction1:22 – Magnitude of the substance use disorder epidemic2:31 – Factors that led to the increase in deaths after 19993:54 – Background on widespread fentanyl use 5:22 – Impact of prescription opioids for chronic pain management on addictions7:52 – HIV healthcare practitioners' role in managing patients with substance use disorders10:15 – Management of withdrawal, including long-term management options18:33 – Harm reduction strategies and the use of naloxone to prevent overdose deaths23:04 – Review of new data showing reduction in overdose deaths in the United States24:19 – Closing remarks and expectations for the next 10 yearsIAS–USA resources on substance use disorders: -- MATE Act CME - https://www.iasusa.org/dea-compliant-cme-resource-center/-- Fellow Resources: https://www.iasusa.org/fellow-student-resources/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Andrew Pavia from the University of Utah about influenza A, specifically the H5N1 strain. Dr Pavia describes the progression of H5N1 and its recent impacts on poultry and other animal populations, including an overview of a recent outbreak among dairy cattle and whether there is a risk to humans exposed on farms and the milk supply at large. They discuss how influenza vaccines are determined each year and the timing of when best to recommend vaccination. They describe treatment options for influenza and their effectiveness against H5N1. Finally, they address public health measures taken during influenza outbreaks and the COVID-19 pandemic, offering lessons learned for future influenza outbreaks in humans.0:00 – Introduction1:32 – Overview of influenza2:54 – Human susceptibility to influenza5:20 –Types of influenza and evolution of H5N1 from birds to mammals9:24 – Natural history of transmission in humans12:34 – Current outbreak of H5N1 in dairy cattle and risk to the milk supply      16:48 – Overview of influenza vaccines and immunity 18:47 – Optimal time to get the influenza vaccine and combined vaccination for COVID-19 23:36 – Treatment options with onset of influenza symptoms and H5N1 is resistance  30:00 – Lessons learned from public health measures taken to protect against outbreaks of influenza and COVID-19 __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

En este episodio platicamos con el CEO y director general de SAAG ( Shanghai Auto Assembly Group) en México que tiene la labor de llevar al éxito a dos marcas que me parecieron muy interesantes Bestune que trae SUVs y un sedán, pero se trata de una marca muy nueva en China que se produce en una planta en China donde fabrican vehículos de lujo, y vaya que el diseño de Bestune les llamará la atención, así como el interior de sus vehículos. Y en el caso de la marca JIM trae a México pickups ideales para el trabajo o para la aventura según sea tu caso, pero tienes que conocer cómo llegó a México este grupo y que vehículos tendremos en nuestro mercado y cuáles son los planes de la marca para este 2024 y 2025. No te pierdas este episodio que realmente fue muy interesante conocer todo acerca de este grupo que ya está en México. 

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Timothy Wilkin from the University of California San Diego about the human papillomavirus (HPV) and anal cancer with options for screening, prevention, and vaccination. They provide an overview of HPV and the types of HPV that lead to cancer. They discuss screening and prevention for anal cancer at HIV and PrEP clinics. They also discuss the findings of the ANCHOR study that demonstrated that high-resolution anoscopy screening detects and prevents anal cancer caused by HPV. Finally, they review HPV vaccination, its effectiveness, and the challenges with uptake of the vaccine in the population at large.0:00 – Introduction1:32 – Overview of HPV3:01 – HPV and cancer4:43 – Screening and prevention for anal cancer at HIV and PrEP clinics9:38 – Findings of the ANCHOR study – efficacy of high resolution anoscopy in detecting anal cancer caused by HPV.11:32 – Barriers to screening and treatment15:05 – HPV vaccination - recommendations and efficacy 18:10 – Challenges with HPV vaccination uptake24:30 – Next ten years of HPV and closing remarksResources and articles:Single dose HPV vaccine articlehttps://pubmed.ncbi.nlm.nih.gov/35693874/ANCHOR trialhttps://pubmed.ncbi.nlm.nih.gov/35704479/CDC OI HPV guidelineshttps://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/humanInternational Anal Neoplasia Society (guidelines and HRA training)https://www.iansoc.org__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Ute Vaughn has become almost a regular at White Stallion Ranch over the last two decades. We love her and the feeling is mutual!  In 2004, Ute moved to Tucson Arizona to follow her passion for the Southwest Art. She is the artist in residences at White Stallion Ranch and belongs to several local art organizations - Artists of the Southwest, SAACA, SAAG, APRA art division, etc. She says it best “I have been an artist all my life. My passion for art, color and life is expressed in my vibrant paintings, which are inspired by animals, nature, symbols and the mystical. My favorite mediums are watercolor, for the flow and translucency, and acrylic for the versatility and texture. My main desire in all my paintings and art classes is to inspire creativity and touch the heart.”

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Paul Volberding from the University of California San Francisco about long COVID and new long COVID disability guidelines. They discuss the symptoms and causes of long COVID and where to find treatment. Dr Volberding discussed his work with the National Academy of Medicine, which recently released a report on long COVID disability guidelines. 0:00 – Introduction1:53 – What is long COVID? How does someone know if they have it? 6:22 – Risk factors and causes of long COVID11:51 – Treatments for and research on long COVID 14:14 – When is long COVID a disability? Disability recommendations from the National Academy of Medicine on long COVID19:53 – How does someone with long COVID get help?23:54 - Closing Remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Peter Chin-Hong from the University of California San Francisco to get an update on important emerging infections. They discuss the current outbreak of COVID-19 and trends in the epidemiology of the disease. They also address emerging measles cases and the underlying pathophysiology of the disease. They also discuss the impact of vaccine disinformation on the risk of measles transmissibility. Finally, they address emerging infections such as avian flu, vaccine developments, and address others like respiratory syncytial virus (RSV) and pertussis.0:00 – Introduction1:42 – Status of the current COVID-19 outbreak3:48 – Update on treatments and vaccination for COVID-19 11:53 – Overview of measles and transmissibility15:30 – Measles herd immunity and vaccine disinformation19:50 – Other emerging infections and vaccine developments23:21 – Closing thoughts __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Raphael Landovitz from the UCLA Medical School about the latest information on HIV prevention via Preexposure Prophylaxis, or PrEP. They discuss the history of PrEP and early efficacy and then move into a discussion of the evolution of PrEP from episodic dosing to longer-acting therapies. The episode also highlights recent research and how that may impact the future of PrEP dosing.0:00 - Introduction1:59 - History of Preexposure Prophylaxis, or PrEP 5:39 - Why initial PrEP regimens were not 100% effective12:01 - Discussion of episodic PrEP and 2-1-1 regimens16:22 - How longer-acting therapy has been shown to be superior to episodic dosing20:29 - LEVI syndrome - what is it?25:05 - What the future holds for PrEP 29:18 - Closing Remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 20 - The Impact of GLP-1 Receptor Agonists with Dr Suman SrinivasaIn this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Suman Srinivasa from Harvard Medical School about the impact of GLP-1 receptor agonists on diabetes and obesity. They discuss the mechanisms, benefits, and current and potential applications, including their use by people with HIV. The episode also highlights future prospects and challenges, including access to medication.00:00 Introduction01:42 Understanding GLP-1 Receptor Agonists03:19 Mechanisms and Benefits of GLP-1 Receptor Agonists05:34 Clinical Applications and Insurance Challenges09:56 GLP-1 Receptor Agonists in HIV Patients15:50 Future Prospects and Broader Applications23:37 Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In Episode 93 of Aarna's News, host Aarna Sahu sits down with Neda Emami, the innovative founder and CEO of SAAG.io. With a background in biomedical engineering and a passion for both business and the great outdoors, Neda has created a groundbreaking platform that's revolutionizing outdoor gear rentals. Join us as Neda shares her journey from the medical device industry to launching SAAG.io, the "Airbnb for outdoor gear," and discusses how her love for entrepreneurship and adventure drives her mission to make outdoor activities affordable and accessible for everyone. --- Support this podcast: https://podcasters.spotify.com/pod/show/aarna-sahu/support

In this episode, we dive deep into the world of extended reality (XR) and artificial intelligence (AI) with Sorob Louie, a visionary entrepreneur and the technical force behind SAAG and VirtuLabs. Louie shares his extensive experience in bridging the gap between complex technological concepts and user-friendly applications, highlighting his journey from leading roles in various software companies to founding and co-founding groundbreaking startups. Discover how Sorob's passion for innovation and his commitment to excellence have led to creating immersive experiences and AI solutions for some of the biggest names in the industry, including Apple, Google, Nike, Samsung, Meta, and Salesforce. With expertise ranging from DevOps and automation to programming and 3D/2D development, Louie's work is at the forefront of transforming how we interact with technology. Join us as Sorob Louie discusses the challenges and rewards of pushing the boundaries of XR and AI, his insights into the future of technology, and his advice for aspiring entrepreneurs looking to make their mark in the tech world. This show is supported by www.matchrelevant.com. A company that helps venture-backed Startups find the best people available in the market, who have the skills, experience, and desire to grow. With over a decade of experience in recruitment across multiple domains, they give people career options to choose from in their career journey.

 This episode of Going anti-Viral features an IAS–USA Dialogue titled "Latest Update on Urgent Viral Outbreaks," which is a panel discussion held on June 11, 2024. Dr Paul A. Volberding from the University of California San Francisco serves as moderator and welcomes three distinguished panelists: Dr Carlos del Rio from Emory University, Yvonne Maldonado from Stanford University, and Dr Peter Chin-Hong from the University of California San Francisco. The episode covers various pressing topics, including updates on COVID-19, avian flu, MPOX, measles, and other viral diseases. Discussions touch on vaccines, their effectiveness, public health approaches, and current research.00:00 Introduction to Going Antiviral Podcast01:21 COVID-19 Current Issues and Personal Experiences06:11 Long COVID and Paxlovid Study07:59 Global Perspective on COVID-1913:59 COVID-19 Vaccination Updates23:52 Avian Flu: Current Concerns and Insights29:15 The Threat of Avian Flu29:46 Understanding H5N2 and Its Impact33:09 The Ongoing MPOX Outbreak37:02 Global Public Health Challenges49:51 Travel Vaccines and Precautions56:31 The Importance of RSV Vaccination58:14 Concluding Remarks and Resources__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 18 - CROI 2024 Insights: Future Prospects of HIV Management and Cardiovascular Health with Dr Todd Brown Recorded May 3, 2024This episode discusses the evolving landscape of HIV-related metabolic complications and cardiovascular health. Dr Michael Saag and Dr Todd Brown cover insights from CROI 2024, key studies on blood pressure management, the cardiovascular benefits of statins, and the promising role of GLP-1 receptor agonists in treating diabetes, obesity, and cardiovascular disease in people with HIV.00:00 Introduction01:56 Blood Pressure Management in HIV09:56 The Impact of Statins on Cardiovascular Health18:07 The Revolutionary Role of GLP-1 Receptor Agonists in HIV Management27:01 Looking Ahead: The Future of HIV Treatment and Management29:21 Closing Remarks and Future Directions__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 17 - CROI 2024 Insights: Progress and Challenges in HIV Antiretroviral Therapy with Dr Barbara Taylor Recorded May 2, 2024 This episode of Going anti-Viral with Dr Michael Saag hosts Dr Barbara Taylor. They discussed topics covered at CROI 2024, including the 95-95-95 goal, long-acting antiretroviral therapies, mental health challenges in HIV care, and the potential for long-acting treatments in other viral diseases like hepatitis C.  00:00 Introduction and Remembering Dr Scott M. Hammer 00:27  CROI 2024 Highlights 02:55 Exploring the 95-95-95 Goal and Challenges in HIV Epidemic Control 09:01 Innovations in Long-Acting Antiretroviral Therapies 14:11 Advancements in Hepatitis C and B Therapies 16:51 COVID-19 Treatments and Resistance Concerns 19:26 Addressing Mental Health in HIV Care__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 16 -  Insights on HIV Cure by Stem Cell Transplant with Dr Ravindra Gupta Recorded Live at CROI 2024 on March 3, 2024 In this episode of Going anti-Viral, Dr Michael Saag hosts Dr Ravindra Gupta. Dr Gupta is the infectious diseases expert who led the team that treated Adam Castillejo, also known as ‘The London Patient,' the second person known to have been cured of HIV. The discussion, recorded on March 3, 2024, at the Conference on Retroviruses and Opportunistic Infections (CROI), focused on the intricate process of finding a suitable stem cell donor, the immunologic and virologic considerations around the transplant process, and the collaborative medical team effort involved.  00:00 Introduction 00:30 The London Patient 03:05 Finding the CCR5∆32 Stem Cell Match 04:21 Clinical Challenges on the Transplant Journey 06:58 Post-Transplant Monitoring and Milestones 15:53 Reflecting on the Journey 18:51 Closing Thoughts and Acknowledgments__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, host Dr Michael Saag interviews Adam Castillejo, known as the London patient, who is the second person to have been cured of HIV infection. The discussion, recorded on March 3, 2024, at The Conference on Retroviruses and Opportunistic Infections (CROI), touches on Adam's initial HIV diagnosis in London during the early 2000s, the societal stigma and personal impact of the diagnosis, and his dual battle with HIV and cancer. Adam shares the complex journey of his treatment, including the failure of initial interventions and the ultimate success of a bone marrow transplant from a donor with a CCR5 delta 32 mutation, leading to his cure of HIV and cancer. The conversation delves into the technical aspects of bone marrow transplant, the emotional and physical challenges Adam faced during recovery, and the continued stigma he experiences even post-cure. The episode reflects on the broader implications of Adam's story for HIV research and societal perceptions of the disease.00:00 Introduction01:10 Adam's Early Struggle with HIV Diagnosis02:46 Confronting Stigma and Finding Support05:26 The Battle Against Cancer and Mental Health Challenges08:35 The Turning Point: Bone Marrow Transplant15:14 The Journey of Recovery17:29 Life After the Cure22:37 Concluding Thoughts__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 14 - HIV Treatment with Long-Acting Injectables with Dr Aadia Rana Recorded Live at CROI 2024 on March 4, 2024In this episode, Dr Michael Saag and Dr Adia Rana discuss a breakthrough study on using a long-acting injectable HIV treatment with conditional economic incentives for individuals who were unable to take oral therapy. Presented at CROI 2024, the study's positive outcomes offer an effective option for certain individuals with no other options for continuing oral antiretroviral therapy.For further reading, please visit the link below.Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel 00:00 Introduction to the Podcast and Guest 00:50 Exploring Adherence Challenges and Study Insights 03:27 The Evolution of HIV Treatment: From Oral to Injectable Therapies 10:59 Study Results: A New Alternative for Select Individuals with Limited Treatment Options 16:05 Navigating Real-World Applications and Ethical Considerations 21:08 Reflecting on the Journey and Looking Ahead 25:21 Closing Thoughts and Future Directions__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

The Heartland Institute's Donald Kendal, Chris Talgo, and Linnea Lueken present episode 443 of the In The Tank Podcast. Heartland's Socialism Research Center just released a new book, Socialism At A Glance. Socialism at a Glance attempts to fill that educational deficiency, providing a succinct summary of socialism's origins and rise in modern history while also giving detailed case studies of some of the most infamous socialist regimes that rose to power in the 20th century, including some that still exist to this day. Also, is the political rhetoric getting more polarized in America? Are the left and right getting further apart?OPENING CHIT CHAT - CLIMATE AT A GLANCEClimate At A Glance Apphttps://climateataglance.com/app/PRIMARY TOPIC - SOCIALISM AT A GLANCE BOOKNew Book - Socialism At A Glancehttps://a.co/d/awZWYKXTampa Bay Times - Florida lawmakers want communism lessons in all grades. The bill is headed to DeSantishttps://www.tampabay.com/news/florida-politics/2024/03/06/florida-lawmakers-want-communism-lessons-all-grades-bill-is-headed-desantis/YAF - New YAF Poll: What is Socialism? More Than Half of Students Can't Accurately Define Ithttps://yaf.org/news/new-yaf-poll-what-is-socialism-more-than-half-of-students-cant-accurately-define-it/Axios - Exclusive poll: Young Americans are embracing socialismhttps://www.axios.com/2019/03/10/exclusive-poll-young-americans-embracing-socialismSECONDARY TOPIC - POLARIZATION IN AMERICANBC News - Here's what's driving America's increasing political polarizationhttps://www.nbcnews.com/meet-the-press/meetthepressblog/s-s-driving-americas-increasing-political-polarization-rcna89559ANES - THE ANES GUIDE TO PUBLIC OPINION AND ELECTORAL BEHAVIORhttps://electionstudies.org/data-tools/anes-guide/anes-guide.html?chart=affective_polarization_parties

Episode 13 -  Advancements in STI Prevention: Insights from Dr Jean-Michel Molina Recorded Live at CROI 2024 on March 3, 2024In this episode of Going anti-Viral, Dr Michael Saag and Dr Jean-Michel Molina discuss recent developments in STI prevention, focusing on doxycycline as post-exposure prophylaxis (DoxyPEP) and the evaluation of a meningococcal vaccine for gonorrhea prevention in the ANRS Doxyvac trial. Recorded at CROI 2024, Dr Molina shares insights from clinical trials, including challenges with data analysis and implications for future STI prevention and vaccine research.00:00 Introduction to the Podcast and Guest 00:30 Innovative Approaches in Clinical Care with Dr Jean-Michel Molina00:54 Exploring the Impact of Doxycycline and Vaccines on STIs01:50 Challenges and Insights from Clinical Trials04:29 The Journey from Interim Analysis to Final Results09:27 Addressing Data Discrepancies21:05 Future Directions in STI Prevention and Vaccine Research26:46 Closing Thoughts and the Importance of Trustworthy Research__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 12 - New Study on Treatments for Non-Alcoholic Fatty Liver Disease in People With HIV With Dr Jordan Lake Recorded Live from CROI 2024In this episode, Dr Michael Saag speaks with Dr Jordan Lake live from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). They discuss the prevalence of non-alcoholic fatty liver disease (NAFLD) among people with HIV and explore the effectiveness of the GLP-1 receptor agonist semaglutide, commonly used to treat diabetes and aid in weight loss, to treat NAFLD. Future areas of research are considered, including maintenance strategies post-weight loss and a placebo-controlled version of the study.00:02 Introduction and Welcome00:44 Discussion on Non-Alcoholic Fatty Liver Disease in People With HIV01:56 Role of HIV in Non-Alcoholic Fatty Liver Disease02:43 Understanding the Inflammation and Fat Accumulation in the Liver04:38 Exploring the Impact of Nucleoside Therapy on Non-Alcoholic Fatty Liver Disease06:37 Potential Treatments for Non-Alcoholic Fatty Liver Disease07:35 The Role of Semaglutide in Treating Non-Alcoholic Fatty Liver Disease13:36 The Importance of Routine Assessment for Non-Alcoholic Fatty Liver Disease15:37 Exploring New Drugs for Treating Non-Alcoholic Fatty Liver Disease18:49 The Challenges and Future Directions in Non-Alcoholic Fatty Liver Disease Research22:25 Conclusion and Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 11 - Innovations in Vaccine Research: Single Cell Immunity Development With Dr Fabian Otte Recorded Live from CROI 2024In this podcast episode, Dr Michael Saag converses with Dr Fabian Otte, a molecular biologist at the University of Basel in Switzerland, live from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). Dr Otte shares insights into the ongoing development of an innovative SARS-CoV-2 vaccine that employs a single-cell immunity development approach. Highlighting its potential benefits, such as broader and longer-lasting immunity compared with mRNA vaccines. This pioneering vaccine research might also extend to other RNA viruses in the future. 00:02 Introduction to the Podcast and Guest 00:28 Discussion on the Development of Next-Generation SARS-CoV-2 Vaccines 00:50 Exploring a Single-Cell Immunity Approach 01:10 Understanding the Vaccine Development Process 02:42 The Potential of the New Vaccine 03:13 Challenges and Advantages of the New Vaccine 05:07 The Impact of the Vaccine on Immune Response__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 10 - Harnessing the Power of Bacteriophages With Dr Robert SchooleyIn this podcast episode, host Dr Michael Saag speaks with Dr Robert “Chip” Schooley, a distinguished Professor of Medicine in the Division of Infectious Diseases and Global Public Health at the University of California San Diego. They discuss the revolutionary potential of bacteriophages, viruses that can infect and kill bacteria. They detail the research efforts and case studies involved in understanding the potential deployment of bacteriophages as a medical treatment. The discussion also highlights the necessity for clinical trials and future research involving genetically engineered phages.00:02 Introduction and Guest Profile01:51 The Growing Problem of Antimicrobial Resistance02:55 Understanding Bacteriophages04:21 The History and Use of Bacteriophages in Labs05:45 The Role of Bacteriophages in Molecular Biology11:43 The Journey of Treating a Patient with Bacteriophages19:19 The Future of Bacteriophage Therapy31:05 Closing Remarks and Podcast Outro__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 9 - Understanding The Implementation of Doxycycline Post-Exposure Prophylaxis (DoxyPEP) and Addressing Sexually Transmitted Infections with Dr Annie Luetkemeyer In this episode of Going anti-Viral, Dr Michael Saag has an insightful discussion with Dr Annie Luetkemeyer, a professor of medicine in the Division of HIV, Infectious Diseases, and Global Medicine at Zuckerberg San Francisco General at the University of California San Francisco.  Centering around the state of sexually transmitted infections in the United States, rising cases, strategies for control, and the promising role of doxycycline post-exposure prophylaxis (DoxyPEP)00:02 Introduction to the Podcast01:31 Discussion on the State of Sexually Transmitted Infections05:21 Exploring the Concept of Post-Exposure Prophylaxis07:19 Understanding the Implementation of DoxyPEP10:23 Effectiveness of DoxyPEP17:41 Potential Side Effects and Concerns of DoxyPEP22:37 Future Prospects of DoxyPEP in STI Prevention28:04 Conclusion and Final Thoughts28:46 Podcast Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 8 - A Historical Overview of The HIV/AIDS Epidemic, Prevention and Intervention Methods, and Future Strategies with Dr Susan BuchbinderIn this episode of the Going anti-Viral podcast, host Dr Michael Saag speaks with Dr Susan Buchbinder, a professor of medicine, epidemiology, and biostatistics at the University of California, San Francisco. They discuss the HIV/AIDS epidemic, tracing its history from its rise in the early 80s to its current status. The conversation covers the efficacy of different preventive and treatment strategies, such as community engagement, behavioral changes, condom use, pre-exposure prophylaxis (PrEP), and the prospects of a future HIV vaccine.00:02 Introduction to the Podcast00:31 Guest Introduction: Dr Susan Buchbinder01:10 History of the HIV Epidemic05:01 The Role of Community in HIV Prevention06:30 Prevention and Interventions07:40 The Importance of HIV Testing10:28 The Revolution of PrEP in HIV Prevention12:42 The Challenges in Ending the HIV Epidemic22:18 The Future of HIV Prevention24:55 Conclusion and Final Thoughts__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Flavours of Punjab. Full Indian English Breakfast. Paratha. Homemade Yogurt. AromasBurnt Turmeric. Masra Di Dal. Saag. Makki Ki Roti. Anda Bhurji. Semiya. Wonders of the Tandoor. Chole Bhature. More Coriander, Please. Tarka. Diner's Choice: Gin Edition. Cocktails Garnishes, Spices & Accoutrements. Personal Stories. Breaking the Narrative.www.crazyco.ukCrazy Co's Instagram: @teamcrazycoParamjit's Instagram: @thecrazykaurBruce's Instagram: @thecrazysinghLick the Plate's Instagram and TikTok: @licktheplatepodcastInstrumentals, mixing & mastering of the theme Song "Lick the Plate" courtesy of Adam Farrell: @farrell33a on InstagramBe Inclusive Hospitalityhttps://bihospitality.co.uk/Additional Music & Sound Effects - Music provided by https://slip.streamTrack: "Wine Glass Different Clink Soft 02"Free Download / Stream: https://slip.stream/tracks/321a50dc-3bc1-44ba-85a5-0ca8db1b3819?utm_source=attribution Hosted on Acast. See acast.com/privacy for more information.